⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26385627 | 0.84 | — | — | |
| SCHEMBL3056172 | 0.84 | — | — | |
| SCHEMBL26385628 | 0.84 | — | — | |
| SCHEMBL23983526 | 0.82 | ACHE (0.40) | — | |
| SCHEMBL24172544 | 0.79 | HRH3 (0.35) | — | |
| SCHEMBL25494070 | 0.77 | HSD11B1 (0.32) | — | |
| SCHEMBL107340 | 0.74 | — | — | |
| SCHEMBL357244 | 0.72 | — | — | |
| SCHEMBL13665428 | 0.72 | HSD11B1 (0.30) | — | |
| SCHEMBL22702658 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | claimed |
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. | 2007-05-24 | — | — | US | claimed |
| WO-2022140427-A1 | SOS1 INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022120118-A1 | NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2021105481-A1 | NOVEL COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105474-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| EP-3736277-A1 | SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS | Lupin Limited (IN) | 2020-11-11 | — | — | EP | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2007046548-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| EP-0658546-B1 | Novel 3-pyrazolecarboxamide derivatives with cannabinoid receptor affinity | SANOFI SYNTHELABO (FR) | 2001-05-23 | — | — | EP | disclosed |
| US-5462960-A | Very good affinity for cannabinoid receptor; having psycho-tropic activity | SANOFI (FR) | 1995-10-31 | — | — | US | disclosed |
| EP-0658546-A1 | Novel 3-pyrazolecarboxamide derivatives with cannabinoid receptor affinity | SANOFI (FR) | 1995-06-21 | — | — | EP | disclosed |
| EP-0042570-B1 | 20-DEOXYROSARAMICIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1983-10-19 | — | — | EP | disclosed |
| EP-0042570-A1 | 20-Deoxyrosaramicin derivatives, process for their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1981-12-30 | — | — | EP | disclosed |
| US-4279896-A | Novel 20-imino macrolide antibacterial agents | SCHERING CORPORATION (US) | 1981-07-21 | — | — | US | disclosed |